SARS News and Research

RSS

Study addresses potential interrelations between AID/APOBECs and the SARS-CoV-2 virus

Together with their multifaceted action mechanisms, activation-induced cytidine deaminase (AID) and so-called APOBEC proteins are important factors in the body's immune response and offer fast and effective protection against a large number of DNA and RNA viruses.

7 Jul 2021

Real-world evidence for effectiveness of vaccination against 4 SARS-CoV-2 VOCs in Canada

Toronto-based researchers recently conducted a study to determine the effectiveness of BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and ChAdOx1 (AstraZeneca) vaccines against symptomatic COVID-19 infection caused by the Alpha, Beta, Gamma, and Delta variants between December 2020 to May 2021.

7 Jul 2021

Vaccinate big cats? New report shows SARS-CoV-2 Delta variant infecting endangered lions

There is evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infecting animals such as ferrets, fruit bats, and cats. New research led by Vijendra Pal Singh from the ICAR-National Institute of High Security Animal Disease in India suggests it might be time to vaccinate the big cats as well. Their report details SARS-CoV-2 infection in nine Asiatic lions caused by the SARS-CoV-2 Delta variant (B.1.617.2).

7 Jul 2021

SARS-CoV-2 Lambda variant spreading rapidly in South America, report reveals

A new research paper by researchers in Peru describes a new variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) known as the Lambda variant (C.37). The Lambda variant was first reported in Lima, Peru, in December 2020, and from April 2021, nearly all the coronavirus infections in the country are caused by it.

7 Jul 2021

Synthetic defective SARS-CoV-2 could be used as a self-promoting antiviral therapy

What if the COVID-19 virus could be used against itself? Researchers at Penn State have designed a proof-of-concept therapeutic that may be able to do just that. The team designed a synthetic defective SARS-CoV-2 virus that is innocuous but interferes with the real virus's growth, potentially causing the extinction of both the disease-causing virus and the synthetic virus.

7 Jul 2021

Study shows antibody titers after natural SARS-CoV-2 infection last longer than previously thought

A recent study by researchers from the United Kingdom (UK) revealed that antibody levels associated with protection against reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are likely to last from 1.5 to 2 years on average and that the protection from severe infection may be present for several years.

7 Jul 2021

COVID-19 vaccination may be stemming evolution of “fitter” SARS-CoV-2 variants

Researchers in the United States and India have presented the first known evidence that the rollout of coronavirus disease 2019 (COVID-19) vaccination is restricting the evolutionary and immune escape pathways accessible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

6 Jul 2021

Moderna’s COVID-19 vaccine elicits durable T cell memory and antibody responses

Researchers in the United States have shown that Moderna’s mRNA-1273 coronavirus disease 2019 (COVID-19) vaccine induces durable antibody and T cell responses to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are comparable to those seen in cases of COVID-19 caused by natural SARS-CoV-2 infection.

6 Jul 2021

Plant compounds inhibit Mpro of SARS-CoV-2 and HCoV-229E in vitro

A group of researchers recently discussed their findings that a group of plant flavonols and dihydroflavonols exhibit antiviral efficacy against both SARS-CoV-2 and HCoV-229E.

6 Jul 2021

SARS-CoV-2 infects and replicates in the salivary glands, study finds

In Brazil, researchers at the University of São Paulo's Medical School (FM-USP) have discovered that SARS-CoV-2 infects and replicates in the salivary glands.

6 Jul 2021

Eight new research projects to explore COVID-19 variants of concern in Canada

Eight new research projects are getting underway in Canada to investigate COVID-19 variants of concern (VOCs) and variants of interest (VOIs).

6 Jul 2021

Study provides a reliable early prognostic biomarker for COVID-19 severity

In a retrospective, multi-centre cohort study conducted by researchers from Nanjing University, Huazhong University of Science and Technology, Jinling Hospital and the Second Hospital of Nanjing, a microRNA-like small RNA encoded by SARS-CoV-2 was identified in the serum of COVID-19 patients, which can be developed as a non-invasive biomarker for stratification of severe patients from mild/moderate ones and for identification of high-risk individuals before clinical manifestation of severe symptoms.

6 Jul 2021

Laboratory manufactured protein spikes mimic key features of SARS-CoV-2 virus

A new international study has found that the key properties of the spikes of SARS-CoV-2 virus which causes COVID-19 are consistent with those of several laboratory-developed protein spikes, designed to mimic the infectious virus.

6 Jul 2021

Angiotensin II type 1 receptor-targeting autoantibodies may increase COVID-19 severity

A team of US-based scientists recently demonstrated that pro-thrombotic autoantibodies that target angiotensin II type 1 receptor (AT1R) may be associated with endothelial complications observed in coronavirus disease 2019 (COVID-19), a novel disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

6 Jul 2021

Serum testosterone status recovery an accurate predictor of survival in male COVID-19 patients

In a study available on the medRxiv* the preprint server, researchers from Spain showed that testosterone trajectories are very accurate individual predictors of survival in male patients with COVID-19. To better understand the relationship between testosterone levels and disease severity, they studied a group of male and female COVID-19 patients assessing their serum and blood biomarkers in association with outcome of disease.

6 Jul 2021

Mutations in the Epsilon variant contribute to SARS-CoV-2 immune evasion

Three mutations in the Epsilon coronavirus spike protein dampen the neutralizing potency of antibodies induced by current vaccines or past COVID infections.

6 Jul 2021

Study examines evolution and avidity of anti-SARS-CoV-2 IgG antibodies after mRNA vaccination

New research released on the medRxiv* preprint server has measured antibody responses in 71 mRNA vaccinated adults (54 vaccinated with Pfizer and 17 vaccinated with Moderna).

6 Jul 2021

Study explores the effects of SARS-CoV-2 (and other betacoronaviruses) on cellular mRNA processing

A new study has been released on the bioRxiv* preprint server, which deals with a comprehensive survey on alternative splicing concerning SARS-CoV-2 infection. This study has also included two other betacoronavirurses (SARS-CoV and MERS), a control set of unrelated viruses, and a bacterium, namely, Streptococcus pneumonia. The study findings suggest that several cellular parameters are affected owing to a betacoronavirus infection, which in turn affects some genes and invariably various biological functions.

6 Jul 2021

Developing a face mask that can detect COVID-19

A face mask has been developed that can detect COVID-19. News-Medical spoke to the researchers behind this idea to find out more about how it works.

6 Jul 2021

COVID-19 recovered vaccinated individuals more protected from Delta variant

The B.1.617 lineage of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first detected in October 2020, has led to new outbreaks of the infection and new waves of the pandemic. This infectious lineage has resulted in the generation of sub-lineages such as B.1.617.1 (Kappa), B.1.617.2 (Delta) and B.1.617.3.

6 Jul 2021

SARS News and Research

Study addresses potential interrelations between AID/APOBECs and the SARS-CoV-2 virus

Real-world evidence for effectiveness of vaccination against 4 SARS-CoV-2 VOCs in Canada

Vaccinate big cats? New report shows SARS-CoV-2 Delta variant infecting endangered lions

SARS-CoV-2 Lambda variant spreading rapidly in South America, report reveals

Synthetic defective SARS-CoV-2 could be used as a self-promoting antiviral therapy

Study shows antibody titers after natural SARS-CoV-2 infection last longer than previously thought

COVID-19 vaccination may be stemming evolution of “fitter” SARS-CoV-2 variants

Moderna’s COVID-19 vaccine elicits durable T cell memory and antibody responses

Plant compounds inhibit Mpro of SARS-CoV-2 and HCoV-229E in vitro

SARS-CoV-2 infects and replicates in the salivary glands, study finds

Eight new research projects to explore COVID-19 variants of concern in Canada

Study provides a reliable early prognostic biomarker for COVID-19 severity

Laboratory manufactured protein spikes mimic key features of SARS-CoV-2 virus

Angiotensin II type 1 receptor-targeting autoantibodies may increase COVID-19 severity

Serum testosterone status recovery an accurate predictor of survival in male COVID-19 patients

Mutations in the Epsilon variant contribute to SARS-CoV-2 immune evasion

Study examines evolution and avidity of anti-SARS-CoV-2 IgG antibodies after mRNA vaccination

Study explores the effects of SARS-CoV-2 (and other betacoronaviruses) on cellular mRNA processing

Developing a face mask that can detect COVID-19

COVID-19 recovered vaccinated individuals more protected from Delta variant

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News